Rob Lambkin‐Williams

6.6k citations

74 papers · 4.5k indexed · 1 hit paper · h-index 31

Impact in

Epidemiology top 0.5%
- Respiratory viral infections research
- Influenza Virus Research Studies
- Pneumonia and Respiratory Infections
Infectious Diseases top 1%
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research

Papers in

Epidemiology 69
- Influenza Virus Research Studies 54
- Respiratory viral infections research 41
Infectious Diseases 32
- Viral gastroenteritis research and epidemiology 13
- SARS-CoV-2 and COVID-19 Research 8
- Viral Infections and Outbreaks Research 5

Co-authors: John Oxford Anthony Gilbert Tom Wilkinson John P. DeVincenzo Shobana Balasingam Xiao-Ning Xu Andrew J. McMichael Cecilia Chui
Journals: Vaccine (10 papers)PLoS ONE (6 papers)The Journal of Infectious Diseases (4 papers)Antiviral chemistry & chemotherapy (4 papers)Influenza and Other Respiratory Viruses (3 papers)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Rob Lambkin‐Williams

74 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans 2012 · 766 citations

Peers

Countries citing papers authored by Rob Lambkin‐Williams

Since Specialization

Citations

This map shows the geographic impact of Rob Lambkin‐Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Lambkin‐Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Lambkin‐Williams more than expected).

Fields of papers citing papers by Rob Lambkin‐Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob Lambkin‐Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Lambkin‐Williams. The network helps show where Rob Lambkin‐Williams may publish in the future.

Co-authors

The 25 scholars most cited alongside Rob Lambkin‐Williams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rob Lambkin‐Williams Line = papers co-authored together Rob Lambkin‐Williams links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A COVID‐19 human viral challenge model. Learning from experience Influenza and Other Respiratory Viruses ·Rob Lambkin‐Williams, John P. DeVincenzo	2020	9
2	Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases Influenza and Other Respiratory Viruses ·P. Jacob Bueno de Mesquita, Jonathan S. Nguyen‐Van‐Tam, Ben Killingley, Joanne Enstone, Rob Lambkin‐Williams, Anthony Gilbert, Alex Mann, John Forni, Jing Yan, Jovan Pantelic, Michael L. Grantham, Donald K. Milton	2020	5
3	The effective rate of influenza reassortment is limited during human infection PLoS Pathogens ·王仲倍, Micah T. McClain, Gavin J. D. Smith, David E. Wentworth, Rebecca Halpin, Xudong Lin, Amy Ransier, Timothy B. Stockwell, Suman R. Das, Anthony Gilbert, Rob Lambkin‐Williams, Geoffrey S. Ginsburg, Christopher W. Woods, Katia Koelle, Christopher J. R. Illingworth	2017	33
4	A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model PLoS ONE ·D. Doijer, Katherine Trudeau, Julie Mori, Andrew Catchpole, Filip Begić, Edward J. Murray, Ganesh Balaratnam, Anthony Gilbert, Alex Mann, E. Arduin, Rob Lambkin‐Williams	2016	5
5	Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model PLoS ONE ·D. Doijer, Nicolas Noulin, Andrew Catchpole, Hosnieh Fathi, Edward J. Murray, Alex Mann, Minal Vasanawala, Ganesh Balaratnam, Filip Begić, Anthony Gilbert, Rob Lambkin‐Williams	2016	9
6	Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM) Journal of Virological Methods ·Syahadatul Khalillah Khairi, Carl Laxton, 임재훈, Karvounaraki Stefanie Kalff-Lena, Paul R. Shockley, Andrew Catchpole, E. Donnall Thomas, Filip Begić, LMZ Esmond, Alison Boyers, Ayushi Raz, Nicolas Noulin, Rob Lambkin‐Williams, Edward J. Murray	2015	6
7	Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study New England Journal of Medicine ·John P. DeVincenzo, Richard J. Whitley, Richard L. Mackman, Erin A. Dandes, Lisa Harrison, Mohammed Ahmed Khaled Seif Aleslam Ahmed, Stephen McBride, Rob Lambkin‐Williams, Robert Jordan, Yan Xin, Srini Ramanathan, Thomas G. O’Riordan, Sandra A. Lewis, Xiaoming Li, Seth Toback, Shao‐Lee Lin, Jason W. Chien	2014	256
8	RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus European Respiratory Journal ·Lindsey Cass, Kazuhiro Ito, Catherine E. Charron, Pete Strong, Mehedi Hassan Pavel, Anthony Gilbert, Rob Lambkin‐Williams, Alex Mann, Garth Rapeport	2013	3
9	Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections Journal of Clinical Virology ·Micah T. McClain, Lawrence P. Park, Bradly P. Nicholson, Timothy Veldman, Aimee K. Zaas, R. Jay Turner, Rob Lambkin‐Williams, Anthony Gilbert, Geoffrey S. Ginsburg, Christopher W. Woods	2013	56
10	Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus American Journal of Respiratory and Critical Care Medicine ·John P. DeVincenzo, Tom Wilkinson, Akshay Vaishnaw, Jeff Cehelsky, Rachel Meyers, Saraswathy V. Nochur, Lisa M. Harrison, 万寿雄寺脇, Alex Mann, Chung Chueh Chang, John Oxford, ian Lin, Leonor Sanmartín Albertos, Zoia Khaletska, 이이영, Preston H. Dorsett, Rene Alvarez, Rob Lambkin‐Williams	2010	237
11	Gene Expression Signatures Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans Cell Host & Microbe ·Aimee K. Zaas, Minhua Chen, Jay B. Varkey, Timothy Veldman, Alfred O. Hero, Joseph E. Lucas, Yongsheng Huang, Ronald B. Turner, Anthony Gilbert, Rob Lambkin‐Williams, Mutsumi Iizuka, Bradly P. Nicholson, Stephen F. Kingsmore, Lawrence Carin, Christopher W. Woods, Geoffrey S. Ginsburg	2009	281
12	Lack of Evidence for Complete Resistance of Peripheral Blood Mononuclear Cells to HIV-1 and HIV-2 Infection Viral Immunology ·Ali A. Al‐Jabri, Rob Lambkin‐Williams, John Oxford	2008	3
13	Flu: Effect of Vaccine in Elderly Care Home Residents: A Randomized Trial Journal of the American Geriatrics Society ·Fiona Gaughran, Rebecca Walwyn, Rob Lambkin‐Williams, Paul Whelan, 岡崎英人, John Oxford, Alastair Macdonald, (unknown)	2007	14
14	Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection Respiratory Research ·Sayyad Mohd. Afzal, Linda Preinfalk, D. Hull, Duane Charbonneau, Rob Lambkin‐Williams, John Oxford	2007	22
15	Human Genetics and Responses to Influenza Vaccination PubMed ·Rob Lambkin‐Williams, Patricia Novelli, John Oxford, Colin Gelder	2004	38
16	A hypothesis: the conjunction of soldiers, gas, pigs, ducks, geese and horses in Northern France during the Great War provided the conditions for the emergence of the “Spanish” influenza pandemic of 1918–1919 Vaccine ·John Oxford, Rob Lambkin‐Williams, A. Sefton, R. S. Daniels, Alex J. Elliot, Richard G. Brown, Débora Gil	2004	71
17	Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors Clinical Microbiology and Infection ·John Oxford, Emmanuel O. Ogunkolati, Shobana Balasingam, Anita Mann, Patricia Novelli, Rob Lambkin‐Williams	2003	210
18	Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine Vaccine ·John Oxford, Ali A. Al‐Jabri, Rob Lambkin‐Williams, A.M. Palache, Douglas Fleming	2003	12
19	Associations between Human Leukocyte Antigens and Nonresponsiveness to Influenza Vaccine The Journal of Infectious Diseases ·Colin Gelder, Rob Lambkin‐Williams, Keith Hart, Douglas Fleming, O. Martin Williams, Mike Bunce, Kenneth I. Welsh, Sara E. Marshall, John Oxford	2002	90
20	Rapid antibody response to influenza vaccination in “at risk” groups Vaccine ·Rob Lambkin‐Williams, John Oxford, Biao Li, Ali A. Al‐Jabri, D Fleming	2000	10

About Rob Lambkin‐Williams

Rob Lambkin‐Williams is a scholar working on Epidemiology, Infectious Diseases, Modeling and Simulation, Immunology and Virology, having authored 74 papers that have together received 4.5k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (54 papers), Respiratory viral infections research (41 papers), Viral gastroenteritis research and epidemiology (13 papers), Immune Response and Inflammation (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers), Immune Cell Function and Interaction (7 papers), COVID-19 epidemiological studies (6 papers) and Viral Infections and Outbreaks Research (5 papers). The work is most often cited by research in Epidemiology (3.1k citations), Infectious Diseases (1.4k citations), Immunology (1.1k citations), Modeling and Simulation (146 citations) and Agronomy and Crop Science (226 citations). Rob Lambkin‐Williams has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include John Oxford, Anthony Gilbert, Tom Wilkinson, John P. DeVincenzo, Shobana Balasingam, Xiao-Ning Xu, Andrew J. McMichael, Cecilia Chui, N. A. Roberts and Dirk B. Mendel. Their work appears in journals such as Vaccine, PLoS ONE, The Journal of Infectious Diseases, Antiviral chemistry & chemotherapy and Influenza and Other Respiratory Viruses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact